Immunohistochemical staining of Amyloid Precursor Protein  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Amyloid Precursor Protein [Polyclonal] Antibody (cGMP).

$ 135.00$ 435.00
Please Select Product Options Below To View The Catalog Number.

Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Rabbit Undetermined

Product NumberDescriptionPrice
QIVD68-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD68-0.5ml Size: 0.5 ml, Format: Concentrate $ 255.00
QIVD68-1ml Size: 1 ml, Format: Concentrate $ 435.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:


Bioactivity (test results eg. IU/ml):

SKU: QIVD68-0.1ml
Amyloid Precursor Protein General Information
Alternate Names
Molecular Weight
86.9 kDa
Chromosomal Location
q21.3 [chr: 21] [chr_start: 25880550] [chr_end: 26171128] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolAPP
Entrez Gene ID351
RefSeq Protein Accession(s)NP_001191230; NP_001191231; NP_001129602; NP_000475; NP_001191232; NP_958817; NP_958816; NP_001129488; NP_001129601; NP_001129603
RefSeq mRNA Accession(s)NM_001204302; NM_001204303; XM_024452075; NM_001136016; NM_001136129; NM_001136130; NM_000484; NM_001204301; NM_201414; NM_001136131; NM_201413;
RefSeq Genomic Accession(s)NG_007376; NC_000021
UniProt ID(s)P05067
PharmGKB ID(s)PA24910
KEGG Gene ID(s)hsa:351
Associated Diseases (KEGG IDs)Alzheimer disease 1 (AD1) [MIM:104300]: A familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. {ECO:0000269|PubMed:10097173, ECO:0000269|PubMed:10631141, ECO:0000269|PubMed:10656250, ECO:0000269|PubMed:10665499, ECO:0000269|PubMed:10677483, ECO:0000269|PubMed:10867787, ECO:0000269|PubMed:11063718, ECO:0000269|PubMed:11311152, ECO:0000269|PubMed:11528419, ECO:0000269|PubMed:12034808, ECO:0000269|PubMed:1302033, ECO:0000269|PubMed:1303239, ECO:0000269|PubMed:1303275, ECO:0000269|PubMed:1415269, ECO:0000269|PubMed:1465129, ECO:0000269|PubMed:15201367, ECO:0000269|PubMed:15365148, ECO:0000269|PubMed:15668448, ECO:0000269|PubMed:1671712, ECO:0000269|PubMed:1678058, ECO:0000269|PubMed:1908231, ECO:0000269|PubMed:1925564, ECO:0000269|PubMed:1944558, ECO:0000269|PubMed:8267572, ECO:0000269|PubMed:8290042, ECO:0000269|PubMed:8476439, ECO:0000269|PubMed:8577393, ECO:0000269|PubMed:8886002, ECO:0000269|PubMed:9328472, ECO:0000269|PubMed:9754958}. The disease is caused by mutations affecting the gene represented in this entry.; Cerebral amyloid angiopathy, APP-related (CAA-APP) [MIM:605714]: A hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease. Some affected individuals manifest progressive aphasic dementia, leukoencephalopathy, and occipital calcifications. {ECO:0000269|PubMed:11409420, ECO:0000269|PubMed:12654973, ECO:0000269|PubMed:16178030, ECO:0000269|PubMed:20697050, ECO:0000269|PubMed:2111584}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of Amyloid Precursor Protein .
This antibody reacts with a 95-100 kDa protein. This antibody recognizes amyloid precursor proteins APP695, APP751 and APP770. Amyloid precursor protein and APP-like proteins are transmembrane glycoproteins with a similar modular domain structure.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment Citrate Buffer pH 6.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Polyclonal
Anti-Amyloid Precursor Protein Antibody Clone: Polyclonal
Host and Isotype: Rabbit Undetermined
Recommended Positive Control Sample: Brain
Cellular Localization of Antibody Polyclonal Staining: Cytoplasmic, extracellular
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: A synthetic peptide corresponding to C-terminal of human APP.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Amyloid Precursor Protein Information for Pathologists


Amyloid beta (A4) precursor protein (APP) is part of the type 1 transmembrane protein family. The APP gene is located on chromosome 21 and encodes for a cell surface receptor and transmembrane precursor protein. There are three homologs of APP: APP, APLP1 and APLP2 (Mol Neurodegener 2011;6:27). Cleavage of APP sequentially by beta secretase (rate limiting step) and gamma secretase produces beta amyloid (amyloid beta, A4, Abeta) peptides of 40 - 43 amino acids, as well as other peptides that have transcriptional, antimicrobial, or antifungal activities (Curr Opin Neurol 2000;13:377). The beta amyloid sequence is unique to APP and is not present in APLP1 or APLP2.

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Amyloid Precursor Protein [Polyclonal] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title




  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Amyloid Precursor Protein [Polyclonal] Antibody (cGMP).